A cyclosporin A/maltosyl-α-cyclosdextrin complex for inhalation therapy of asthma

Hiroaki Fukaya, A. Iimura, K. Hoshiko, T. Fuyumuro, S. Noji, T. Nabeshima

研究成果: Article

19 引用 (Scopus)

抄録

The inhalation of cyclosporin (Cs)A to the lung is limited by its hydrophobic properties. In order to improve the poor solubility of CsA, cyclodextrin (CD) was evaluated for its suitability for dry powder inhaler formation, and the benefit of an inhaled CsA/CD complex in vivo was demonstrated. The solubilising effect of CDs on CsA was measured by high-performance liquid chromatography. Ciliostatic activity and haemolysis were determined to assess some safety profiles of CDs. The efficacy of an inhaled CsA/CD complex was evaluated by eosinophil infiltration into the bronchoalveolar lavage fluid in actively sensitised mice. CDs markedly improved the poor solubility of CsA. The ciliostatic and haemolytic activities of maltosyl-α-CD were the weakest of all the tested CDs. CsA inhaled alone showed inhibitory effects on allergen-induced eosinophilia. Inhalation of the complex of CsA with maltosyl-α-CD, where the dose of CsA was approximately nine-times less than that of CsA inhaled alone, also inhibited eosinophil accumulation significantly, with a longer duration of action in comparison with the response to CsA alone. Thus the effective dose of cyclosporin A could be reduced by formation of a complex with maltosyl-α-cyclodextrin, and a wider therapeutic safety margin by inhalation of cyclosporin A as a complex with maltosyl-α-cyclodextrin could be expected.

元の言語English
ページ(範囲)213-219
ページ数7
ジャーナルEuropean Respiratory Journal
22
発行部数2
DOI
出版物ステータスPublished - 01-08-2003
外部発表Yes

Fingerprint

Respiratory Therapy
Cyclosporine
Cyclodextrins
Asthma
Inhalation
Eosinophils
Solubility
Dry Powder Inhalers
Safety
Bronchoalveolar Lavage Fluid
Eosinophilia
Hemolysis
Allergens
High Pressure Liquid Chromatography
Lung
maltosyl-cyclodextrin
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

これを引用

Fukaya, Hiroaki ; Iimura, A. ; Hoshiko, K. ; Fuyumuro, T. ; Noji, S. ; Nabeshima, T. / A cyclosporin A/maltosyl-α-cyclosdextrin complex for inhalation therapy of asthma. :: European Respiratory Journal. 2003 ; 巻 22, 番号 2. pp. 213-219.
@article{d055a8bafe3a411fa4c609dd2202cfb5,
title = "A cyclosporin A/maltosyl-α-cyclosdextrin complex for inhalation therapy of asthma",
abstract = "The inhalation of cyclosporin (Cs)A to the lung is limited by its hydrophobic properties. In order to improve the poor solubility of CsA, cyclodextrin (CD) was evaluated for its suitability for dry powder inhaler formation, and the benefit of an inhaled CsA/CD complex in vivo was demonstrated. The solubilising effect of CDs on CsA was measured by high-performance liquid chromatography. Ciliostatic activity and haemolysis were determined to assess some safety profiles of CDs. The efficacy of an inhaled CsA/CD complex was evaluated by eosinophil infiltration into the bronchoalveolar lavage fluid in actively sensitised mice. CDs markedly improved the poor solubility of CsA. The ciliostatic and haemolytic activities of maltosyl-α-CD were the weakest of all the tested CDs. CsA inhaled alone showed inhibitory effects on allergen-induced eosinophilia. Inhalation of the complex of CsA with maltosyl-α-CD, where the dose of CsA was approximately nine-times less than that of CsA inhaled alone, also inhibited eosinophil accumulation significantly, with a longer duration of action in comparison with the response to CsA alone. Thus the effective dose of cyclosporin A could be reduced by formation of a complex with maltosyl-α-cyclodextrin, and a wider therapeutic safety margin by inhalation of cyclosporin A as a complex with maltosyl-α-cyclodextrin could be expected.",
author = "Hiroaki Fukaya and A. Iimura and K. Hoshiko and T. Fuyumuro and S. Noji and T. Nabeshima",
year = "2003",
month = "8",
day = "1",
doi = "10.1183/09031936.03.00018202",
language = "English",
volume = "22",
pages = "213--219",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "2",

}

A cyclosporin A/maltosyl-α-cyclosdextrin complex for inhalation therapy of asthma. / Fukaya, Hiroaki; Iimura, A.; Hoshiko, K.; Fuyumuro, T.; Noji, S.; Nabeshima, T.

:: European Respiratory Journal, 巻 22, 番号 2, 01.08.2003, p. 213-219.

研究成果: Article

TY - JOUR

T1 - A cyclosporin A/maltosyl-α-cyclosdextrin complex for inhalation therapy of asthma

AU - Fukaya, Hiroaki

AU - Iimura, A.

AU - Hoshiko, K.

AU - Fuyumuro, T.

AU - Noji, S.

AU - Nabeshima, T.

PY - 2003/8/1

Y1 - 2003/8/1

N2 - The inhalation of cyclosporin (Cs)A to the lung is limited by its hydrophobic properties. In order to improve the poor solubility of CsA, cyclodextrin (CD) was evaluated for its suitability for dry powder inhaler formation, and the benefit of an inhaled CsA/CD complex in vivo was demonstrated. The solubilising effect of CDs on CsA was measured by high-performance liquid chromatography. Ciliostatic activity and haemolysis were determined to assess some safety profiles of CDs. The efficacy of an inhaled CsA/CD complex was evaluated by eosinophil infiltration into the bronchoalveolar lavage fluid in actively sensitised mice. CDs markedly improved the poor solubility of CsA. The ciliostatic and haemolytic activities of maltosyl-α-CD were the weakest of all the tested CDs. CsA inhaled alone showed inhibitory effects on allergen-induced eosinophilia. Inhalation of the complex of CsA with maltosyl-α-CD, where the dose of CsA was approximately nine-times less than that of CsA inhaled alone, also inhibited eosinophil accumulation significantly, with a longer duration of action in comparison with the response to CsA alone. Thus the effective dose of cyclosporin A could be reduced by formation of a complex with maltosyl-α-cyclodextrin, and a wider therapeutic safety margin by inhalation of cyclosporin A as a complex with maltosyl-α-cyclodextrin could be expected.

AB - The inhalation of cyclosporin (Cs)A to the lung is limited by its hydrophobic properties. In order to improve the poor solubility of CsA, cyclodextrin (CD) was evaluated for its suitability for dry powder inhaler formation, and the benefit of an inhaled CsA/CD complex in vivo was demonstrated. The solubilising effect of CDs on CsA was measured by high-performance liquid chromatography. Ciliostatic activity and haemolysis were determined to assess some safety profiles of CDs. The efficacy of an inhaled CsA/CD complex was evaluated by eosinophil infiltration into the bronchoalveolar lavage fluid in actively sensitised mice. CDs markedly improved the poor solubility of CsA. The ciliostatic and haemolytic activities of maltosyl-α-CD were the weakest of all the tested CDs. CsA inhaled alone showed inhibitory effects on allergen-induced eosinophilia. Inhalation of the complex of CsA with maltosyl-α-CD, where the dose of CsA was approximately nine-times less than that of CsA inhaled alone, also inhibited eosinophil accumulation significantly, with a longer duration of action in comparison with the response to CsA alone. Thus the effective dose of cyclosporin A could be reduced by formation of a complex with maltosyl-α-cyclodextrin, and a wider therapeutic safety margin by inhalation of cyclosporin A as a complex with maltosyl-α-cyclodextrin could be expected.

UR - http://www.scopus.com/inward/record.url?scp=0042026803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042026803&partnerID=8YFLogxK

U2 - 10.1183/09031936.03.00018202

DO - 10.1183/09031936.03.00018202

M3 - Article

C2 - 12952250

AN - SCOPUS:0042026803

VL - 22

SP - 213

EP - 219

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 2

ER -